S
Semprus BioSciences
Permanent, non-leaching surface modifications for medical devices
About Semprus BioSciences
Semprus BioSciences was a biomedical company that developed a proprietary surface modification technology to reduce complications from implanted medical devices, such as infection and blood clots. The company was founded in 2006 as SteriCoat by David L. Lucchino and Dr. Christopher Loose, spinning out of the Langer Lab at the Massachusetts Institute of Technology (MIT).
The founders' backgrounds were complementary; Lucchino, with an MBA from MIT's Sloan School of Management, provided the business leadership, while Dr. Loose, who earned his Ph.D. in Chemical Engineering from MIT, led the technology development. Lucchino had previous experience co-founding a biotechnology investment firm and working at a venture capital fund. Dr. Loose's doctoral research under the guidance of renowned biomedical engineer Robert Langer formed the scientific basis of the company. Their business plan won entrepreneurial competitions at MIT, Harvard, and Oxford.
The company's core product was the Semprus Sustain™ Technology, a non-leaching, covalently bonded polymer surface. This technology worked by creating a dense layer of polymers that attracted water, forming a physical barrier that mimicked human cells to prevent the adhesion of microbes and proteins, thereby reducing the risk of thrombosis and infection. Unlike traditional coatings that can dissolve over time, the Semprus surface was grown from the device material itself, designed for long-term durability. The initial market focus was on vascular access catheters, with plans to expand to other devices like orthopedic implants. The company raised a total of $28.5 million in venture capital and secured over $8 million in federal funding. In June 2012, Semprus BioSciences was acquired by Teleflex Incorporated, a global provider of medical devices, for an upfront payment of $30 million with potential for an additional $50 million in milestone-based payments. Following the acquisition, Semprus's first product, a catheter using the Sustain™ technology, received FDA 510(k) clearance and the CE Mark in Europe.
Source: Dealroom company dataKnowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITION✓Exit | Jun 2012 | $0 | — | Teleflex | — |
| GRANT✓Other financing | Oct 2011 | $1M | — | Undisclosed | — |
Growth signals
Latest recorded traffic for Semprus BioSciences is 50 monthly website visits. Semprus BioSciences's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A5 investors entered at this stage
5AM Ventures
Pangaea VenturesSR One
GSK- FPFoundation Medical Partners
Other known investors2 additional known investors
Carnegie Mellon University
Teleflex
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Semprus BioSciences on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Semprus BioSciences’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.







